FLT1 and thyroid gland carcinoma: Can inhibit multiple targets, including RET, MET, and VEGFR-1/2/3, to inhibit the growth of tumor cells, angiogenesis, and metastasis. For differentiated thyroid cancer refractory to RAI, it can also control tumor growth and metastasis by inhibiting the kinases related to tumor angiogenesis and tumor cell proliferation